Novo Nordisk Drug Pipeline

Novo Nordisk maintains a substantial clinical portfolio, with 72 active trials out of 708 registered since 2008. These active trials span from Phase 1 through Phase 4, with the largest number currently in Phase 3 development. The company’s research activity extends across 10 therapeutic areas, but is heavily concentrated in Metabolic diseases, which accounts for 67% of active programs. Within Metabolic, the leading indications are Obesity, with a significant cluster of Phase 3 trials, followed by Type 2 Diabetes. Other areas of focus within Metabolic include Type 1 Diabetes, general Diabetes indications, and NASH/NAFLD. Beyond Metabolic, Novo Nordisk also has active trials in Cardiovascular, Musculoskeletal, Renal, Rare Disease, and CNS indications, though these represent a smaller proportion of the overall portfolio. The high concentration of trials in Phase 3, particularly within Obesity, suggests a focus on near-term clinical milestones.